SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Amgen Inc. (AMGN)
An SI Board Since December 1996
Posts SubjectMarks Bans Symbol
1906 112 0 AMGN
Emcee:  trevor john wilkinson Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1306Author has preference for the proteins and peptides and, surprise, has consultedkeokalani'nui-10/11/2006
1305"Novel strategies for stimulating erythropoiesis and potential new treatmentuck-10/11/2006
1304Anyone know what happened to AMG-108 (anti IL1) ?nigel bates-10/6/2006
1303HGSI's anti-CCR5 program in HIV looks a bit promising, though it's only tuck-10/2/2006
1302I got back in just a while ago. AMGN is starting a patient assistance program, tuck-9/28/2006
1301<i>They won't pull it unless post market studies show serious side effDewDiligence_on_SI-9/27/2006
1300Vectibix label: investorshub.com Commentary (FWIW): investorshub.com investorshDewDiligence_on_SI-9/27/2006
1299They won't pull it unless post market studies show serious side effects. Ittechnetium-9/27/2006
1298The postmarketing study must show survival (not PFS) and is presumably in the seDewDiligence_on_SI-9/27/2006
1297FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer Wemopgcw-9/27/2006
1296Reuters now has an update, and the major change is that AMGN must conduct a posttuck-9/27/2006
1295This was stamped 3:52PM; AMGN up to $72.25: >>WASHINGTON, Sept 27 (Reutertuck-9/27/2006
1294<b> Amgen Announces License Agreement with Yeda Research and Development CDewDiligence_on_SI-9/19/2006
1293<i>No fracture data in this.</i> Amgen Presents Denosumab and Sclerkeokalani'nui-9/19/2006
1292Commentary on that Reclast PR: investorshub.comDewDiligence_on_SI-9/17/2006
1291<i>NVS PR</i> Once-Yearly Reclast(R)* Demonstrates Highly Significakeokalani'nui-9/17/2006
1290As Epogen Doses Rise, So Do Warnings: investorshub.comDewDiligence_on_SI-9/14/2006
1289would expect Pani to take over Erbitux's share in time because it is a betteidos-9/13/2006
1288Weeks. Would love to see a "Lucentis." It launched on the very last tuck-9/13/2006
1287Tuck, "so expect launch shortly thereafter" Do you expect launch in idos-9/13/2006
1286Can't say about the bundling, but seems unlikely to me, IMVHO, though the satuck-9/12/2006
1285When does p-mab launch and will it be bundled with the Ara. and NP/NL contract?longaria-9/10/2006
1284citi: AMGN: CMS Revision to EPO Monitoring Policy Provides Added Flexibility mopgcw-8/29/2006
1283Citi: AMGN: Federal Appeals Court Rules on TKT Case: Implications for CERA BUY mopgcw-8/11/2006
1282gs: Amgen Inc. (AMGN): Maintain positive view after meeting with management 52-mopgcw-8/8/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News